Yesterday, FierceBiotech reported how an expert review of a tiny study for Genervon’s ALS drug GM604 had raised serious questions about the data that were provided by the company, which has aroused a furious campaign by ALS sufferers to gain an accelerated FDA approval. Today, in a rare break from the agency’s standard “no comment” approach to experimental drugs, the agency called on the biotech to come clean and publicly release the actual results.

…read more

Source: UPDATED: The FDA challenges Genervon to release data from controversial ALS study


0 No comments